Mozobil (plerixafor) Disease Interactions
There are 3 disease interactions with Mozobil (plerixafor):
Plerixafor (Includes Mozobil) ↔ leukocytosis
Moderate Potential Hazard, Moderate plausibility. Applies to: Leukocytosis
The use of plerixafor in combination with granulocyte-colony stimulating factor increases leukocytes as well as hematopoietic stem cells populations. Caution should be exercised when administering this agent to patients with peripheral blood neutrophil counts above 50,000/mcL. It is recommended to monitor white blood cell counts during therapy.
Plerixafor (Includes Mozobil) ↔ renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction
It is recommended to reduce the dose of plerixafor by one-third to 0.16 mg/kg in patients with moderate to severe renal impairment.
Plerixafor (Includes Mozobil) ↔ thrombocytopenia
Moderate Potential Hazard, Moderate plausibility. Applies to: Thrombocytopenia
The use of plerixafor may cause thrombocytopenia. Care and close monitoring are recommended when using plerixafor in patients with thrombocytopenia. Monitor counts in all patients and then undergo apheresis.
More about Mozobil (plerixafor)
- Mozobil Side Effects
- During Pregnancy
- Dosage Information
- Pricing & Coupons
- En Español
- Drug class: hematopoietic stem cell mobilizer
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.